Together, everyone at Synageva shares a passion and commitment to improving the lives of patients suffering from rare diseases.

We believe that Every Second Counts when discovering, developing, and delivering therapies to these patients.
 

Learn More

 

Synageva BioPharma Corp. is a biopharmaceutical company with headquarters, research and development facilities in Lexington, MA. Our mission is to deliver breakthrough medicines globally for patients suffering from rare, devastating diseases. Our team has a proven track record of delivering life-altering therapies to patients with diseases once considered too rare for developing treatments.

Learn More

News & Events


December 17, 2014
Synageva BioPharma To Present At The 33rd Annual J.P. Morgan Healthcare Conference On Monday, January 12, 2015 At 9:00 A.M. PST

December 15, 2014
Synageva BioPharma Announces Active Investigational New Drug Application For SBC-103 For The Treatment Of Mucopolysaccharidosis IIIB

D
ecember 2, 2014
Synageva BioPharma Completes Rolling Submission Of Biologics License Application To The FDA For Sebelipase Alfa And Submits Marketing Authorization Application To European Medicines Agency

November 10, 2014
Synageva BioPharma Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency At The AASLD Meeting

November 6, 2014
Click here to listen to Sanj K. Patel and Anthony Quinn's Fireside Chat at the Nomura Biotechnology Conference

October 30, 2014
Synageva BioPharma Reports Third Quarter 2014 Financial Results

October 23, 2014
Synageva BioPharma Presents Sebelipase Alfa Data At The NASPGHAN Meeting

October 21, 2014
Synageva BioPharma Starts Rolling Submission Of A Biologics License Application To The FDA For Sebelipase Alfa

June 30, 2014
Synageva BioPharma Reports Positive Top-Line Results From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency

June 3, 2014
Synageva BioPharma Highlights Data Presentations and Satellite Symposium at the European Atherosclerosis Society Congress

May 2, 2014
Synageva BioPharma Announces Satellite Symposium At The National Lipid Association Meeting

April 23, 2014
Click here to read the 2013 Annual Report and letter to Shareholders.

April 21, 2014
LAL Deficiency Disease Review Published In Atherosclerosis

March 4, 2014
Synageva BioPharma Issued U.S. Patent for Treatment of LAL Deficiency

February 13, 2014
Synageva Biopharma Highlights Sebelipase Alfa And LAL Deficiency Data At The Lysosomal Disease Network (LDN) World Symposium

February 12, 2014
Synageva Biopharma Highlights SBC-103 Data At The Lysosomal Disease Network (LDN) World Symposium

    More News